Clinical trial disclosure
Clinical trial disclosure sits at the intersection of securities law and biotech finance, and Financial & Capital Markets firms with exposure to life sciences issuers are operating under active scrutiny from the U.S. Securities and Exchange Commission, which has used Rule 10b-5 and Regulation FD enforcement actions to press hard on selective disclosure of trial data that moves prices. The European Securities and Markets Authority has added pressure through its market abuse framework, particularly where clinical readouts qualify as inside information under MAR Article 7. Compliance teams are not waiting: many are now pre-clearing trial milestone communications against their material nonpublic information policies before investor calls.
Watch
- SEC Rule 10b-5 enforcement pattern around undisclosed Phase III trial failures
- MAR Article 7 threshold: when a trial endpoint becomes inside information
- Regulation FD selective disclosure risk on clinical data shared with analysts pre-announcement
- FINRA suitability review of structured products tied to clinical-stage biotech performance
Recent material activity in Financial & Capital Markets
Active monitoring in place across Financial & Capital Markets. Material developments related to clinical trial disclosure will appear here as they are published.